Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Revolution medicines - What They Never Told You

Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the momentum moving forward.

New cancer drug shows potential to double patients’ survival time

New cancer drug shows potential to double patients’ survival time

The Independent UK

New pancreatic cancer drug nearly doubles survival time in patients

New pancreatic cancer drug nearly doubles survival time in patients

Pancreatic cancer is the only cancer with a five-year survival rate that’s below 20%

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Oncology Stock Just Hit New All-Time Highs

Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Wall Street analysts are overwhelmingly bullish on RVMD, although sentiment is mixed across other platforms. Today’s Featured Stock Valued...

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Friday.

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Revolution Medicines, Inc. (NASDAQ:RVMD) stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.

Revolution Medicines's Return On Capital Employed Overview

Revolution Medicines (NASDAQ:RVMD) brought in sales totaling $7.58 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.44%, resulting in a loss of $57.65 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Revolution Medicines's Earnings Outlook

Revolution Medicines's Earnings Outlook

Revolution Medicines (NASDAQ:RVMD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Revolution Medicines will report an earnings per share (EPS) of $-0.77.

Children's Place And 2 Other Stocks Bought By Insiders

Children's Place And 2 Other Stocks Bought By Insiders

Although US stock futures traded higher this morning on Friday, there were a few notable insider trades.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

the American Cancer Society

Hewlett Packard

Ollie Bargain Outlet

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

367,972 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play